Skip to main content

Table 4 Geometric mean titers and fold increase in pneumococcal immunoglobulin and opsonophagocytic antibodies after PCV-13 vaccination

From: Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy

Baricitinib (N = 106) Baseline Week 5 Week 12
Immunoglobulin (μg/mL)
 Serotype 4 Geometric mean (95% CI) 0.48 (0.41, 0.56) 1.39 (1.05, 1.83) 1.20 (0.91, 1.59)
Fold increase (95% CI) 2.8 (2.2, 3.6)* 2.6 (2.0, 3.2)*
 Serotype 6B Geometric mean (95% CI) 0.89 (0.72, 1.12) 3.32 (2.37, 4.63) 3.10 (2.22, 4.35)
Fold increase (95% CI) 3.6 (2.8, 4.5)* 3.2 (2.6, 4.0)*
 Serotype 14 Geometric mean (95% CI) 1.71 (1.30, 2.25) 4.19 (3.12, 5.64) 4.66 (3.45, 6.28)
Fold increase (95% CI) 2.5 (2.0, 3.2)* 2.5 (1.9, 3.2)*
 Serotype 23F Geometric mean (95% CI) 0.80 (0.65, 0.99) 2.89 (2.02, 4.14) 2.86 (2.02, 4.05)
Fold increase (95% CI) 3.5 (2.7, 4.5)* 3.4 (2.7, 4.4)*
OI
 Serotype 4 Geometric mean (95% CI) 92.1 (64.8131.0) 1717.9 (1166.0, 2531.1) 1016.8 (688.7, 1501.1)
Fold increase (95% CI) 18.2 (11.8, 28.0)* 11.4 (7.5, 17.2)*
 Serotype 6B Geometric mean (95% CI) 153.8 (103.1, 229.4) 2153.0 (1431.3, 3238.7) 1519.0 (1029.2, 2241.9)
Fold increase (95% CI) 13.2 (8.5, 20.4)* 9.0 (6.0, 13.4)*
 Serotype 14 Geometric mean (95% CI) 270.2 (176.8, 413.1) 1328.2 (934.2, 1888.3) 1152.0 (811.6, 1635.2)
Fold increase (95% CI) 4.9 (3.2, 7.5)* 3.8 (2.5, 5.7)*
 Serotype 23F Geometric mean (95% CI) 50.1 (35.1, 71.5) 627.2 (390.5, 1007.3) 489.3 (314.9, 760.3)
Fold increase (95% CI) 12.1 (8.0, 18.5)* 9.3 (6.3, 13.8)*
  1. *p ≤ 0.001 compared to baseline
  2. CI confidence interval, OI opsonization index